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Abstract 
Nearly five decades following its conception, the Gleason grading system 
remains a cornerstone in the prognostication and management of patients with 
prostate cancer.  In the past few years, a debate has been growing whether 
Gleason score 3+3=6 prostate cancer is a clinically significant disease. Clinical, 
molecular and genetic research is addressing the question whether well 
characterized Gleason score 3+3=6 disease has the ability to affect the morbidity 
and quality of life of an individual in whom it is diagnosed. The consequences of 
treatment of Gleason score 3+3=6 disease are considerable; few men get through 
their treatments without sustaining some harm. We propose a further 
modification of the classification of prostate cancer and drop the label cancer for 
Gleason score 3+3=6 disease.  
 
Introduction 
The American Cancer Society defines cancer as a disease that is caused by the 
abnormal and uncontrolled growth of cells, possesses the ability to invade other 
tissues and, if left untreated, will lead to serious morbidity and eventually death. 
The subject of this Perspective article is important, given that prostate cancer is 
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the second most prevalent cancer in men1. Furthermore, as the overall male 
population ages the prevalence will increase. The International Agency for 
Research on Cancer reported that prostate cancer accounted for 14% of all 
cancers diagnosed in men and >900,000 men were diagnosed with the disease 
throughout the world in 2008 alone. Most of these cancers will have a 3+3=6 
Gleason pattern on diagnosis2. 
 
Nearly five decades after its original conception, the Gleason grading system 
remains the cornerstone of the management of patients with prostate cancer3.  
To this day, this histological classification has upheld its position as the principal 
determinant of disease progression. This prognostic attribute is achieved in a 
rather unusual way.  Most histological grading follows an ordinal scale based on 
the degree of cytological atypia within the cells of a tumour. The Gleason grading 
system does not incorporate any information on cytological parameters.  Instead, 
it is principally established on the architectural pattern, size and spacing of the 
tumour glands rather than the nuclear features of the malignant cells 
themselves.  In addition, the system’s prognostic value has withstood despite 
changes to the way in which grade is determined and score calculated4. 
 
Over the years, it has become widely accepted that Gleason patterns 1 and 2 
diagnosed on prostatic needle biopsy specimens actually represent benign 
proliferations, such as adenosis or atypical adenomatous hyperplasia.  A number 
of concerns mean that it is now time to evaluate whether Gleason pattern 3 that 
has been well characterised by modern techniques should be considered similar 
to pattern 1 and 2. Clearly, a change in designation of Gleason pattern 3 to a 
noncancer status would have profound consequences.  In this Perspective article, 
we argue that most of these consequences are likely to be beneficial to those men 
diagnosed with Gleason score 3+3=6 prostate cancer and the viewpoint of 
Gleason pattern 3 prostate cancer as a lethal disease is becoming increasingly 
uncertain5-8.  
 
Evolution of Gleason grading 
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The birth of Gleason grading 
In 1966, Donald Gleason created a unique grading system for prostate cancer 
that was entirely derived from architectural features of the disease using low-
powered microscopy3  With a five-point scale, patterns 1, 2 and 3 represented 
tumours that most closely resembled normal prostatic glands and patterns 4 
and 5 demonstrated an increasingly abnormal glandular architecture. A 
derivative of the patterns was constructed from the sum of the two most 
commonly observed grade patterns and became known as the Gleason score. The 
original description of this system was based on a study in 270 patients, which a 
later study in 1974 expanded to include 1,032 men9. In his early studies, Donald 
Gleason reported that he could duplicate his grading scores during re-
examination of specimens within ±1 score point in 85% of cases3,10. 
Furthermore, he reported that his grading score had a strong prognostic value 
and could predict cancer-specific mortality.  
 
Changes in scoring over time 
Many aspects of the clinical management of men with prostate cancer have 
changed since the conception of the Gleason grading system. To accommodate 
this change in clinical practice, substantial modifications of this system have 
occurred11.  For instance, Gleason pattern 1 and 2 are now considered to 
represent benign proliferations in most instances. 
The problem with the low grades 1–3 that led to this re-evaluation concerned 
their reproducibility.  Biopsy samples were based on a transrectal systematic 
approach that often did not characterize the cancer properly.  Assessment of 
low-grade tumours had the greatest interobserver variability among urological 
pathologists12,13. 
In the contemporary assessment of prostatic needle biopsy samples, Gleason 
grading starts at Gleason pattern 3.  Owing to the advent and regular use of 
immunohistochemistry, many of the specimens originally classified as Gleason 
pattern 1 would now be regarded as atypical adenomatous hyperplasia14,15.  By 
the turn of the millennia, a proposal was made that Gleason patterns 1 and 2 
should not be diagnosed as prostate cancer, regardless of the type of specimen, 
owing to inaccuracies and poor reproducibility between experts14,16. In 2001, the 
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rate of biopsy reports describing Gleason scores of 2–4 was 2.4% and reduced to 
0% by 200617,18. 
In 2005, an adaptation of the Gleason grading system was accepted at a 
consensus conference of international experts in urological pathology under the 
auspices of the International Society of Urological Pathology (ISUP)15,19. This 
adjustment was made to address areas of debate and the existence of 
architectural arrangements that the original scoring system had not accounted 
for, aiming to increase reproducibility and reliability of the evaluation of biopsy 
specimens.  The major changes were the inclusion of poorly formed glands into 
Gleason pattern 4 which would have been previously labelled as Gleason grade 
≤3.  Furthermore the revised definition of Gleason score based on needle biopsy 
samples, which should always include the highest Gleason pattern detected in a 
specimen19. In addition, the new agreement reclassified irregular cribiform 
glands from a pattern 3 to 4.  These modifications resulted in a statistical artefact 
termed the Will Rogers Phenomenon, with improvement of clinical outcomes for 
both Gleason Score 3+3=6 and 3+4=7 prostate cancer20,21. This clarification on 
which architectural elements should be attributed a pattern 4 label effectively 
removed disease with a poor clinical outcome from Gleason score 3+3=6. In 
addition, the amendment resulted in an overall reduction in the risk of morbidity 
and mortality associated with attribution of Gleason pattern 4 compared with 
the classification used before 2005. Thus, any prediction models based on 
samples that were histologically graded before 2005 (which includes nearly all 
models) overestimate the risk associated with Gleason pattern 4 disease that is 
graded using the post-2005 rules.  
The current definition of Gleason pattern 3 consists of disease with discrete 
glandular units that vary in size and shape within the prostatic stroma19.  
Furthermore, individual tumour acini demonstrate a smooth and usually 
rounded edge with an intact basement membrane.  Gleason pattern 4 describes a 
disruption to the form associated with pattern 3: the glandular architecture is no 
longer preserved and the basement membrane is disrupted.  In this sense, the 
threshold between Gleason pattern 3 and pattern 4 is not dissimilar from pTa 
and pT1 in bladder cancer. 
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Changes in biopsy techniques 
Over the past century, we have witnessed continued modifications to the process 
of tissue procurement for analysis by the pathologist.  The methods have 
comprised open biopsy, endoscopic punch biopsy, transperineal (blind or 
ultrasound-guided) or transrectal (finger-guided or ultrasound-guided (TRUS)) 
biopsy, endoscopic resection and, most recently, image-guided biopsy with or 
without image registration22.  At any time point, several different approaches 
have been in use.  Current procedures include 12-core TRUS biopsy, 
transperineal template biopsy and biopsy targeted to an imaging-identified 
lesion23-25. 
Techniques of prostate TRUS biopsy have progressed from systematic sextant to 
12-core biopsies, which demonstrated increased cancer detection rates without 
increasing morbidity22.  Increasing the number of biopsy cores increased 
prostate cancer detection rates including detection of disease without lethal 
potential26. The original error was a random biopsy rather than basing the 
biopsy deployment on the phenotype presenting itself.  Image-guided biopsy is 
used in the diagnosis of the majority of all cancers  The visual area of concern is 
identified before sampling a specific area of abnormality. 
 
When the Gleason grading system was first described the vast majority of men 
presented with advanced disease and tissue was obtained using a few low-gauge  
needles directed into the area of palpable abnormality.  Now, most biopsies are 
performed using thin needles, resulting in specimens that differ from those 
available when the system was created. The use of thinner needles have been 
shown to decrease post-biopsy infection rates at the expense of providing less 
tissue per core.27   
The biopsy method employed influences whether any Gleason pattern 4, if 
present, will be detected.  A biopsy using a 10–12-core transrectal technique can 
miss pattern 4 in up to 50% of patients28.  By contrast, the use of modern MRI-
guided techniques results in very few Gleason pattern 4 cancers being missed29. 
The consequence is that upgrading (the finding that Gleason score at definitive 
pathological assessment following radical prostatectomy is higher than at initial 
biopsy) is significantly reduced30. When standard TRUS biopsy is used during the 
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diagnostic work-up, upgrading occurs in up to 50% of patients28, which means 
that risk stratification at diagnosis was incorrect in half of the patients.  
 
Upgrading 
Sampling imprecision and reproducibility 
The driving force towards increased sampling density or image-guided biopsy is 
a result of the desire to reduce diagnostic imprecision.  This problem most 
commonly becomes evident when patients are upgraded or reclassified when the 
pathological status of their radical prostatectomy specimen is compared to the 
risk attributed to their disease by the pathological assessment of their biopsy 
sample31,32,33.  This phenomenon has been found in all investigations of this topic 
published to date, which report reclassification rates that range between 25% 
and 50%34-37. Reclassification error has been shown to be related to the different 
manner in which Gleason patterns were declared upon assessment of biopsy 
specimen compared with the full histopathology available at step-sectioning 
following radical prostatectomy33. Gleason score upgrading, as well as 
downgrading, is still an important problem when using the latest Gleason 
system, even when accounting for tertiary Gleason patterns in radical 
prostatectomy specimens33.   
Upgrading of disease merely represents sampling imprecision as opposed to a 
mandate for justifying the potential presence of increased-grade disease co-
existing in the prostate.  The occurrence of upgrading highlights a need for 
development in the manner of how we obtain tumour specimens and adoption of 
targeted biopsies using MRI or MRI-ultrasound fusion, which is expected to be 
declared the gold-standard procedure38.  We now have level 1b evidence to 
support the adoption of mpMRI prior to a first prostate biopsy as the standard of 
care39.  In the presence of Gleason score 3+3=6 prostate cancer, upgrading 
should not be confused as a rationale for treating patients with nonhistologically 
confirmed significant disease. 
In addition, problems regarding the reproducibility of Gleason grading, even 
amongst pathologists, have been highlighted40,  This inconsistency would be a 
potential source for inconsistent diagnoses of cancer in patients who are found 
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to have prostatic tissue with a Gleason score 3+3=6.  An agreement on even 
stricter criteria separating Gleason pattern 3 from pattern 4 might be required 
before we are to consider any changes to the nomenclature of prostate cancer, 
and could also include a requirement for centralized review of all equivocal 
specimens. 
Capacity of Gleason pattern 3 to progress 
Evidence is accumulating that shows the lacking ability of low-grade prostate 
cancers to progress to higher-grade disease41 42. One study in 1, 207 patients 
(including 267 men with Gleason score ≤6) who underwent prostatectomy 
between 1982 and 2004 has reported data suggesting that grade is established 
early in tumour pathogenesis41. 
Previous reports of Gleason pattern 3 progressing to higher grades have now 
been primarily attributed to the inherent sampling insufficiencies of using 
conventional TRUS-guided biopsy. In 2014, one team of investigators 
demonstrated that the progression of Gleason pattern 3 to a higher pattern was a 
rare occurrence in men on active surveillance when both initial and follow-up 
targeted biopsies were undertaken in an accurate manner using MRI-ultrasound 
fusion techniques42.  We anticipate that the increased adoption of MRI 
technology in prostate cancer diagnostics and surveillance will enable us to 
monitor disease in a more reliable manner previously possible43. Then we will 
truly be able to determine the upgrading capacity of low-grade prostate cancer. 
 
Clinical outcomes of Gleason 3+3=6 disease 
 
Prostate-cancer-specific mortality 
Over the years, a considerable amount of data has accumulated regarding the 
risk associated with a Gleason pattern 3 attribution.  Some important points 
need to be taken into account when evaluating these data. When we describe 
data on prostate cancer mortality it will, by necessity, be based on patients that 
were treated around 15–20 years ago, which has two implications.  First, 
contemporary review of the original pathology results of these men would result 
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in upgrading to a higher Gleason pattern in a moderate proportion of men. If the 
original assessment result was exclusive pattern 3 then the most probable 
upgrade would be to a Gleason score of 3+411.  Second, the precision of a biopsy 
two decades ago would have been substantially lower than today.  We can, 
therefore, be certain that a considerable minority of men who were classified as 
having exclusive Gleason pattern 3 disease would have harboured a range of 
pattern 4 and an occasional pattern 5 tissues44. The implication is that the 
attribution of Gleason pattern 3 at that time was associated with considerably 
more risk than a contemporary attribution.  This knowledge is useful to us in the 
epidemiological analysis of historical data sets. This systematic bias has the 
effect of rendering our estimations of risk on historical patients as the likely 
worst-case scenario as many of these men would have harboured Gleason score 
>6 if present-day grading systems were utilised. Increasing amounts of data 
demonstrate that patients with pure Gleason pattern 3 disease have negligible 
prostate-cancer-specific mortality.   This assertion is very likely to be true and 
substantiated by the abundance of data of well characterized Gleason pattern 3 
disease, which arises from the tens of thousands of men who have been 
monitored following a radical prostatectomy.  
Peter Albertson was one of the first urologists to alert us to the very low 
propensity of a prostate-cancer-related death conferred by a historical 
attribution of Gleason pattern 3 status45. His report included data from men 
whose disease was given a Gleason score 3+3=6 between 1971 and 1984 and 
underwent conservative management. At 20 years, the prostate cancer death 
rate in this group was 30 deaths per 1000 person years — unchanged from the 
rates at 15 years.  Investigators of another study reported on 223 untreated men 
with localized prostate cancer who were all initially managed with observation 
and androgen deprivation in the presence of symptomatic cancer progression.46 
During a 30-year surveillance period, 12.3% of 65 patients diagnosed with 
Gleason score ≤6 disease using the ISUP 2005 criteria died owing to their 
disease. This proportion translates into 1.4 men out of 1,000 men dying of 
Gleason score ≤6 prostate cancer if monitored for a 10-year period. 
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A contemporary cohort of men with Gleason score 3+3=6 disease who opted for 
active surveillance had a cancer-specific survival of >97% with median follow-up 
period of 22–82 months8.  Furthermore, data that suggest inferior outcomes of 
these men who delay radical therapy is yet to be seen8.  If the mortality in this 
cohort of men remains stable then, again, the question arises whether Gleason 
score 3+3=6 prostate cancer results in any consequential cancer-specific-
mortality. 
In a study from 2015, a team of investigators analyzed 1,829 prostatectomy 
specimens from patients treated between 1992 and 2008,  acknowledging in 
their report that the pathological analyses were not performed according to 
2005 ISUP criteria.47  In this cohort, 451 patients were identified as having 
Gleason score 3+3=6 disease and their  10-year cancer-specific mortality was 
0% and 0.5% in patients with <0.5ml and 0.5–2.49 ml disease volume, 
respectively.  This difference in death rates were not statistically significant.  
Abundant data exist of disease outcomes of tens of thousands of men with well 
characterized Gleason pattern 3 prostate cancer who have been monitored after 
radical prostatectomy48,49.  A report on a cohort of nearly 10,000 men who were 
monitored following radical prostatectomy showed that the cancer-specific 
mortality was 0.03% in men who had pure Gleason pattern 3 disease in their 
radical specimens48. 
The Prostate Cancer Intervention Versus Observation Trial (PIVOT) clearly 
demonstrated that men diagnosed with Gleason score ≤6 prostate cancer do not 
reduce their risk of death (all-cause and cancer-specific mortality) at any interval 
if undergoing radical prostatectomy in comparison with observation50.  
Furthermore, men who were randomly assigned to surgery had a 15% increased 
mortality compared with those assigned to observation for low-grade disease 
(determined by PSA level ≤10ng/ml, Gleason score 3+3=6 and stage T1a–c or 
T2a). 
Taking into account the imprecision of risk attribution in several of these cohorts 
and noting that, today, many of the investigated specimens would be classified as 
Gleason score 3+4=7, this evidence collectively suggests that during a 1–20-year 
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time period pure Gleason pattern 3 disease is associated with a minimal risk of a 
prostate-cancer-related death.  
Metastatic capability  
Most deaths from cancer occur as a result of metastasis and metastatic lymphatic 
involvement is a hallmark of advanced prostate cancer51,52.  Presence of lymph 
node metastasis in patients with prostate cancer is directly associated with a 
poor prognosis and significantly decreased disease-specific and biochemical-
recurrence-free survival53. The notion that Gleason score 3+3=6 disease has a 
substantial, or indeed any, ability to metastasise is increasingly being 
questioned49,54.  
 
A large-scale population study published in 2014 investigated the presence of 
lymph node metastases in patients who underwent radical prostatectomy with 
lymph node sampling following a diagnosis of Gleason score 6 prostate cancer 
between 2004 and 201054.  Only 0.48% of 21,960 patients were found to have 
lymph node metastases.  This proportion was reduced in data from large 
academic centres and the authors suggest that the presence of positive lymph 
nodes in patients diagnosed with Gleason score 6 disease could serve as a proxy 
for assessing the adherence to the 2005 ISUP criteria54. 
 
Similarly, investigators in a study from 2012 used the  2005 ISUP 2005 Gleason 
scoring system to evaluate the potential of Gleason score ≤6 disease to 
metastasize to lymph nodes49.  Using data from 14,123 patients who had 
undergone radical prostatectomy at four large academic centres, the authors 
identified 22 patients with a positive lymph node.  Histopathological re-review 
was undertaken in 19 of these patients demonstrating that all had a primary, 
secondary or tertiary Gleason pattern 4 or pattern 5; specimens from three 
patients were unavailable for re-review and the study was limited by a potential 
observer bias, as all involved pathologists were aware of the nodal metastatic 
status of the patients before re-review. In this setting, Gleason pattern 3 disease 
does not seem associated with a metastatic phenotype. 
In patients with confirmed haematogenous prostate cancer metastasis, the 
skeletal system was affected in 90% of men55.  However, even before ISUP 2005, 
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<1% of men diagnosed with Gleason score 3+3=6 disease were shown to have 
bone metastases56.    
Another study in 178 men with Gleason score 3+3=6 disease of ≤2.5cm3 volume 
found a biochemical reccurrence rate of 0% following radical prostatectomy 
(median follow-up period 84 months)57. 
These studies highlight that if a malignancy does not possess the ability to 
metastasize it fails to adhere to the label of lethal entity and, therefore, does not 
fulfil this classical attribute of cancer. 
 
Two studies from 2013 have suggested that Gleason score 3+3=6 prostate cancer 
can indeed metastasize, resulting in lethal disease58,59.  Nakabayashi et al.58 
highlighted the small number of Gleason score 3+3=6 prostate cancer that 
develops into lethal disease.  In their cohort of 662 men, seven men were 
classified as having died from disease of this grade. Numerous methodological 
flaws of this study have been pointed out, including a lack of centralized review 
and absence of the exact characterization of the biopsy samples and pathological 
techniques used60. All these highlighted weaknesses have been accepted by the 
authors as a limitation to the validity of their conclusion61. 
The widely referenced study by Haffner et al.59 described a lethal metastatic 
clone originating from a low-grade primary tumour lesion. Using whole-genome 
sequencing and molecular pathological analyses the investigators demonstrated 
that the metastases arose from a focus of Gleason score 3+3=6 disease. This 
particular patient did also harbour Gleason pattern 4 disease, but comprehensive 
sequencing of multiple tumour foci could not be performed, as the prostatic DNA 
was 20 years old. Several groups have raised concerns regarding the validity of 
the authors’ findings based on data from a single patient62,63.  
 
Molecular changes of Gleason patterns 
In their seminal papers published in 2000 and 2011, Hanahan and Weinberg 
described the pathogenesis of cancer in six, and subsequently eight, pertinent 
hallmarks applicable to all variations of this disease64,65. We now have mounting 
molecular, proteomic and RNA-based evidence demonstrating that Gleason score 
3+3=6 prostate cancer is either failing to adhere to or to possess each of the six 
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original hallmarks of cancer (TAB 1)66.  For higher-grade, however, an 
abundance of evidence exists that those diseases fulfil all six criteria66.  
Research into the molecular bases of cancers has identified differing and 
exclusive pathologies between the various grades of numerous genitourinary 
malignancies67-69. For prostate cancer, genetic and epigenetic evidence is 
emerging that Gleason score 3+3=6 disease is a distinct entity in comparison 
with its higher-grade counterparts66,70-72.   
The evolution of normal prostatic tissue to high-grade prostate cancer involves 
morphological, chromosomal and developmental alterations. Germline 
mutations and environmental factors lead to synergistic DNA damage and 
oncogenic mutations which, in turn, prime prostatic tissue to transform into a 
malignant state.  The combination of mutations of intracellular tumour 
suppressor genes (for example, PTEN and TP53), overexpression of oncogenes 
(for example, MYC, AKt/mTOR and genes encoding other tyrosine kinases) and 
oncogenic androgen-sensitive fusion products of chromosomal rearrangements 
(for example, TMPRSS2 and ERG) leads to uncontrolled cell proliferation73. 
Genomic analysis of mRNA expression levels of pure Gleason pattern 3 in 
comparison with Gleason pattern 4 disease has demonstrated that Gleason 
pattern 3 tissues are relatively homogenous in the genes that are 
overexpressed74,75.  By contrast, mRNA expression patterns of Gleason pattern 4 
tissue  are unequivocally varied and incorporate a wide range of overexpressed 
genes74,75.  For Gleason pattern 3 disease, little evidence exists for the presence 
of subclonal driver mutations and, instead, these tissues have been shown to 
overexpress genes that primarily control intracellular metabolism. Mutations in 
Gleason pattern 4 disease is broadly linked to the overexpression of genes 
associated with the molecular traits of cancer; that is, those regulating the cell 
cycle, DNA replication and androgen signalling attenuation76.   
 
Studying multifocal cancers, one group of researchers demonstrated that 
Gleason score 3+3=6 prostate cancer diverges early from its higher-grade and 
metastatic counterparts70.  Using laser microdissection and exome sequencing, 
they found that only 9% of high-confidence somatic mutations in Gleason score 
3+3=6 disease were shared with higher-grade disease, whereas the proportion 
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was 82% when comparing high-grade and metastatic foci from lymph nodes.  
Notably, mutations in cancer-associated genes and in the tumour suppressor p53 
signalling pathway were found exclusively in high-grade foci and metastases.   
On a molecular level, using genome-wide DNA sequencing, morphologically 
normal tissue distant from the primary prostate cancer lesion has been shown to 
contain high levels of mutations77.  This finding suggests that the underlying 
mutational processes in morphologically normal and low-grade prostate cancer 
tissue are also occurring in higher-grade disease consistent with a field effect.  
Protocols are in place to evaluate the mutation status in >500 men receiving 
standard-of-care treatment for castration-resistant disease which is hoped to 
provide a systematic approach to define the broader spectrum of genomic 
alterations in progressive lethal disease78. These studies might provide a 
systematic basis to define the broad spectrum of genomic alterations in 
progressive, lethal disease — an essential step in translating early laboratory-
based observations into benefits in patient care78.   Molecular characterization of 
prostate cancer is not expected to replace current clinical and pathological 
information. Instead, incorporation of these additional molecular data into 
current models might provide a more bespoke treatment plan for each 
patient78,67. 
Parallels with other cancers 
Keeping in mind previous adaptations in other genitourinary cancer, the loss of 
the cancer terminology for pure Gleason pattern 3 prostate cancer certainly 
would not be a radical step.  Furthermore, this change would be in keeping with 
modifications made for several other solid-organ cancers. For example, 
numerous calls for ductal carcinoma in situ of the breast to forgo the label of 
carcinoma have been made, primarily led by a multidisciplinary NIH 
consensus79,80.  Similar to Gleason pattern 3 prostate cancer this call for 
relabeling is fundamentally driven by the favourable prognosis and behaviour of 
this particular type of breast cancer. 
In the field of endocrine surgery, a subset of papillary carcinoma of the thyroid 
has been labelled papillary microcarcinoma of the thyroid (PMCT), owing to its 
relatively indolent behaviour.  Similar to Gleason score 3+3=6 prostate cancer, 
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diagnoses of PMCT have increased, mainly because of more frequent use of 
ultrasound-guided fine-needle aspiration biopsy.  Numerous studies and national 
guidelines have advocated discharging patients diagnosed with PMCT from 
future follow-up monitoring or, at most, mere observation  as an appropriate 
management plan as opposed to invasive surgical therapy81-83. 
Over the past several decades, an increasing number of people with chronic 
nonmalignant conditions, such as diabetes, hypertension and 
hypercholesterolaemia, are considered to be diseased, owing to lowered 
threshold values for diagnosis84.  Now, evidence is emerging that instigating 
treatment modalities for the new diagnoses of these diseases is failing to reduce 
morbidity and mortality85-87.   
Urologists specializing in the treatment of superficial bladder cancer succeeded 
in reclassifying a cancer phenotype to a noncancer phenotype. Papillary 
urothelial neoplasia of low malignant potential (PUNLMP) was previously 
categorized within the spectrum of grade 1 bladder cancer.  The 1998 WHO–
ISUP meeting recognized and renamed certain low-grade bladder tumours with 
a particularly good prognosis as PUNLMPs, avoiding the label of cancer88. 
PUNLMPs have been shown to have long-term nonmalignant capacity, as they 
lack any ability to become muscle-invasive or lethal disease  according to the 
literature, thus, they continue to hold the status of a noncancer entity89.  
Clinical comparisons can be made between PUNLMPs in the bladder and Gleason 
pattern 3 lesions in the prostate, but on a cellular level differences between the 
two tumours exist.  Gleason pattern 3 disease demonstrates nuclear atypia of a 
malignant type and no basal cell layer that can be observed for its counterparts 
with higher grades, which in turn pathologically labels Gleason pattern >3 
disease as an invasive disease.  Histologically, PUNLMPs resemble an exophytic 
urothelial papilloma with an increased cellular proliferation that exceeds the 
thickness of normal urothelium90.  Their papillary structures are lined by an 
organized arrangement of urothelial cells that have minimal architectural 
abnormalities and minimal nuclear atypia90.  
Overtreatment, costs and fear 
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Gleason score 3+3=6 prostate cancer has been given numerous labels, including 
low-risk disease, insignificant disease, minimal-risk lesions and indolent lesions 
of epithelial origin (IDLE)5,91.  In this context, dropping the label cancer might not  
be a radical step. 
In oncology, overdiagnosis is defined as the diagnosis of cancers that will not 
clinically manifest itself during an individual’s lifetime or kill their carrier92.  
Overdiagnosis naturally leads to overtreatment.  Little debate exists among 
experts in the field that the current generation of urologists are overtreating 
prostate cancer93-96.  Clinicians are aware that the lifetime risk of substantial 
morbidity and mortality of a patient who has been diagnosed with Gleason score 
3+3=6 prostate cancer is minimal.  However,  when given this diagnosis most 
men still choose to undergo definitive treatment, despite the evidence that they 
will hardly benefit94,95,97. Now, there are signs that this behaviour is starting to 
change and that strategies such as active surveillance are being more widely 
adopted than was previously98.  The reasons for this development are complex 
and include deeply entrenched societal and cultural drivers, as well as more 
widely acknowledged financial and medico-legal imperatives to treat97,99,100. 
Overtreatment occurs in 67% of men diagnosed with low-risk prostate cancer 
and is positively associated with being married and residing in affluent areas97.  
One study found that 64.3% of a cohort of 39,803 men diagnosed with Gleason 
score ≤6 disease underwent some form of aggressive treatment101.  Receiving 
aggressive treatment was significantly associated with men who had a high 
socioeconomic status, were Caucasian or married.  The findings of this study 
have led to calls for future policies to provide more rigid guidelines for the 
deferred treatment of Gleason score 3+3=6 prostate cancer and to offer more 
culturally and sociodemographically tailored counselling for those men at 
greatest risk of overtreatment101. Calculations for the USA show that the ability 
to avoid treating men with low-grade prostate cancer who will never succumb to 
their disease will save US$1.32 billion alone and, more importantly, avoid the 
marked detrimental effect on patients’ quality of life owing to the treatment 
modalities97.   
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A fear of litigation associated with relabeling Gleason score 3+3=6 prostate 
cancer as noncancer may occur with pathologists and urologists100. Indeed, the 
most common reason for nonoperative claims in urology is related to the failure 
to diagnose or treat cancer102.  Concerns have been raised that pathologists could 
potentially be a new group of clinicians who are regularly affected by medical 
liability claims100,103. 
The majority of men visiting their urologist because of lower urinary tract 
symptoms are worried about a diagnosis of prostate cancer above all else104.  
When a man is diagnosed with Gleason score 3+3=6 disease psychological 
factors of the patient have been shown to drive disease management towards 
radical treatment105.  Men of any age have an inherent fear of dying when faced 
with a diagnosis of prostate cancer100,106.  The question arises whether a 
substantial number of men would still choose to undergo radical treatment if 
they were presented with the same prognostic and trifecta statistics but 
dropping the word cancer from their diagnosis of Gleason 3+3=6 disease. 
The grade group system 
The most recent modification to the Gleason score grading system was an 
attempt to create a five-point scale to reflect the range of risk107.  We welcome 
this new system and look forward to its implementation.  The new system 
comprises a five-stage ordinal scale: exclusive Gleason pattern 3 is categorized as 
prognostic Gleason grade group 1; group 2 comprises disease in which a 
secondary pattern 4 is present in a predominant pattern 3; group 3 includes 
tumours in which pattern 4 dominates over pattern 3; group 4 is attributed to 
Gleason score 8 disease; and group 5 is reserved for Gleason score ≥ 9 disease. 
Conclusions 
We propose that our colleagues at ISUP further modify the classification of 
prostate cancer and drop the label cancer for Gleason score 3+3=6 disease. With 
the increased adoption of image-guided techniques to obtain prostatic tissue in a 
more accurate manner, the fear of potentially having missed disease of an 
increased grade will not bias disease reporting. 
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When a patient is given a diagnosis of well characterized Gleason score 3+3=6 
prostate cancer, he has been labelled with a disease status that is associated with 
a higher mortality if treated compared with leaving it untreated.  In addition, the 
consequences of treatment are considerable both in economic terms and in its 
inevitable harms; few men get through their treatments without sustaining some 
harm.  Furthermore, the disease entity that we are describing is distinct from its 
more aggressive counterpart both morphologically and by modern molecular 
characterisation.  Yet, we insist on using the same descriptor for a disease with a 
broad range of risk and also invoke the same word that is linked with 50% 1-
year survival seen in some cancers, such as pancreatic and lung cancer. The 
move to a five-stage ordinal scale that places exclusive Gleason pattern 3 disease 
on the lowest rung of the ladder of risk is a welcome and timely development.   
Some of our colleagues who have opposing views might be apprehensive owing 
to biopsy sampling imprecision and reproducibility, especially when giving a 
certain diagnosis of a ‘benign’ condition following assessment of a needle biopsy 
sample.  Furthermore, in pathological terms, Gleason pattern 3 fulfils multiple 
criteria of cancer.  The large and varied evidence that has accumulated over the 
past decades combined with the reduction in overall risk associated with 
Gleason pattern 3 (owing to reclassification) and modern diagnostic precision 
(virtually eliminating upgrading at radical prostatectomy) suggests that the time 
has come to relegate well characterized Gleason pattern 3 morphological change 
as a potential risk factor for cancer — namely Gleason pattern 4 and pattern 5 — 
and not cancer in its own right.     
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Figure 1.   The pathological, clinical and molecular differences between 
Gleason pattern 3 and 4.  The distinction between Gleason pattern 3 and 
pattern 4 is evident in their heterogeneous molecular characteristics and distinct 
clinical courses.  Factors of pathological assessment must also be taken into 
consideration when differentiating these two patterns of disease.  
  20 
 
Figure 2.  The five-point grade group system of Gleason scoring.  The most 
recent modification to the Gleason grading system resulted in a five-point scale 
reflecting disease risk groups.  Grade group 1 are tissues with exclusive Gleason 
pattern3; group 2 are diseases with predominant pattern 3 but secondary 
pattern 4; group 3 includes those in which pattern 4 dominates over pattern 3; 
group 4 is attributed to Gleason score 8 disease; group 5 is reserved for Gleason 
score ≥ 9 disease.   
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TAB 1 | Molecular distinction of Gleason pattern 3 or score 6 tissue from higher-
grade disease and correlation to the six hallmarks of cancer. 
 
  
Hallmark Study Findings 
1. Self-sufficiency in 
growth signals 
Ross et al.108 Exclusive differential expression of 670 genes between 
Gleason pattern 3 and pattern 4 tissues, including EGF, 
EGFR, MAP2K4, RALA, REPS2, PHLPP, PML, which are all 
established genes associated with growth signalling 
Skacel et al.109 Amplification of ERBB2, - a known proto-oncogene, in 
Gleason pattern 4 compared with pattern 3 tissue 
2. Insensitivity to 
antigrowth signals 
Padar et al.110 Significantly higher frequency of CCND2, involved in 
regulation of cell-cycle G1 to S phase transition, 






Significant upregulation of antiapoptotic BCL2 in higher-
grade compared with Gleason pattern 3 tissue 
True et al.75 Greater expression of antiapoptotic DAD-1 in higher-




Tomlins et al.76 Compared with Gleason pattern 3 tissue, pattern 4 tissue 
showed an attenuated androgen signalling signature, 
similar to metastatic prostate cancer 
Hendriksen et 
al.112 
Of 200 androgen-responsive genes in prostate cancer 
functionally distinct parts of the androgen receptor 
pathway were downregulated in high-grade cancers, 
including decreased HERPUD1, STK39, DHCR24 and 
SOCS2  mRNA expression 
5. Sustained 
angiogenesis 
West et al.113 Upregulation of proangiogenic vascular endothelial 
growth factor in higher-grade compared with Gleason 
pattern 3 tissue 
6. Tissue invasion 
and metastasis 
de Muga et 
al.114  
Upregulation of CXCR4, involved in directing cancer cell 
migration to metastatic sites, in Gleason score >7 tissue 
independent of TMPRSS2–ERG rearrangement 
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